Clinical Research Directory
Browse clinical research sites, groups, and studies.
Low-Dose Naltrexone For ME/CFS: Dose-Finding
Sponsor: University of Alabama at Birmingham
Summary
This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
Official title: Low-dose Naltrexone (LDN) for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Dose-Finding
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2026-07-01
Completion Date
2028-04-01
Last Updated
2026-04-06
Healthy Volunteers
No
Interventions
Low-Dose Naltrexone, 1.5mg
Low-Dose Naltrexone (LDN) is not a commercially available drug and will be compounded for this study. LDN will be taken orally, up to once per day.
Low-Dose Naltrexone, 3.0mg
Low-Dose Naltrexone (LDN) is not a commercially available drug and will be compounded for this study. LDN will be taken orally, up to once per day.
Low-Dose Naltrexone, 4.5mg
Low-Dose Naltrexone (LDN) is not a commercially available drug and will be compounded for this study. LDN will be taken orally, up to once per day.
Low-Dose Naltrexone, 6.0mg
Low-Dose Naltrexone (LDN) is not a commercially available drug and will be compounded for this study. LDN will be taken orally, up to once per day.
Locations (1)
University of Alabama at Birmingham
Birmingham, Alabama, United States